USA

Kevzara of Sanofi and Regeneron fails Phase III Covid-19 trial

Sanofi and Regeneron Pharmaceuticals reported that a Phase III clinical trial of rheumatoid arthritis medication Kevzara (sarilumab) failed to meet its key primary and secondary endpoints in Covid-19 patients who required mechanical ventilation in the U.S. The study compared the 400 mg dose of the drug plus the best supportive …

Read More »